ACUMEN PHARMACEUTICALS INC. - COMMON STOCK

Acumen Pharmaceuticals to Participate in 2023 Bank of America Healthcare Conference

04 май 2023 16:01:00 Источник Nasdaq GlobeNewswire

Acumen Pharmaceuticals to Report First Quarter Financial Results on May 9, 2023

02 май 2023 16:01:00 Источник Nasdaq GlobeNewswire

Acumen Pharmaceuticals Presents in vitro Human Neuron Model for Evaluating Binding of Amyloid Beta Oligomers in Alzheimer’s Disease

28 мар 2023 08:00:01 Источник Nasdaq GlobeNewswire

Acumen Pharmaceuticals Reports Financial Results for Full Year Ended December 31, 2022 and Business Highlights

27 мар 2023 07:00:00 Источник Nasdaq GlobeNewswire

Acumen Pharmaceuticals to Participate in Stifel 2023 Virtual CNS Days

22 мар 2023 16:01:00 Источник Nasdaq GlobeNewswire

Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2022 Financial Results on March 27, 2023

20 мар 2023 16:01:00 Источник Nasdaq GlobeNewswire

Acumen Pharmaceuticals to Participate in the Needham Neuroscience Forum

08 мар 2023 16:01:00 Источник Nasdaq GlobeNewswire

Acumen Pharmaceuticals Completes Enrollment in Phase 1 Trial of ACU193, First Monoclonal Antibody Developed to Selectively Target Toxic Aβ Oligomers in Patients with Early Alzheimer’s Disease

13 фев 2023 08:00:00 Источник Nasdaq GlobeNewswire

Acumen Pharmaceuticals Appoints Derrell Porter, M.D., to its Board of Directors

04 янв 2023 08:00:02 Источник Nasdaq GlobeNewswire

Acumen Pharmaceuticals Reports Third Quarter 2022 Financial Results and Business Highlights

14 ноя 2022 16:01:01 Источник Nasdaq GlobeNewswire

Acumen Pharmaceuticals to Participate in the Stifel Healthcare Conference

09 ноя 2022 16:01:00 Источник Nasdaq GlobeNewswire

Acumen Pharmaceuticals to Report Third Quarter 2022 Financial Results on Nov. 14, 2022

07 ноя 2022 16:01:00 Источник Nasdaq GlobeNewswire

Acumen Publishes Phase 1 Trial Design and Clinical Development Plan for ACU193, an Anti-Amyloid Beta Oligomer Antibody for Alzheimer’s Disease

01 ноя 2022 08:00:02 Источник Nasdaq GlobeNewswire

Acumen’s ACU193, an Anti-Amyloid Beta Oligomer Antibody, Granted FDA Fast Track Designation for Alzheimer's Disease

24 окт 2022 08:00:01 Источник Nasdaq GlobeNewswire

Acumen Pharmaceuticals Reports Financial Results for Second Quarter 2022 and Business Highlights

15 авг 2022 16:05:02 Источник Nasdaq GlobeNewswire

Acumen Pharmaceuticals to Report Second Quarter 2022 Financial Results on August 15, 2022

08 авг 2022 16:15:00 Источник Nasdaq GlobeNewswire

Acumen presents poster describing method to standardize amyloid beta oligomer assays supporting therapeutic development for early Alzheimer’s disease

01 авг 2022 10:30:00 Источник Nasdaq GlobeNewswire

Acumen Pharmaceuticals to Participate in Upcoming Investor and Scientific Conferences

26 июл 2022 16:15:00 Источник Nasdaq GlobeNewswire

Acumen Pharmaceuticals Reports Financial Results for First Quarter 2022 and Business Highlights

16 май 2022 16:05:01 Источник Nasdaq GlobeNewswire

Acumen Pharmaceuticals to Report First Quarter 2022 Financial Results on May 16, 2022

11 май 2022 17:08:41 Источник Nasdaq GlobeNewswire